Inotuzumab ozogamicin in older patients with acute lymphoblastic leukaemia: premises and promises
- 1 February 2018
- journal article
- editorial
- Published by Elsevier in The Lancet Oncology
- Vol. 19 (2) , 159-160
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 studyThe Lancet Oncology, 2018
- Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).Journal of Clinical Oncology, 2017
- Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysisBlood, 2017
- Historical Controls?Haematologica, 2017
- Patient Characteristics and Treatment Patterns in Elderly Patients Newly Diagnosed with Acute Lymphoblastic Leukemia (ALL) Using 100% Medicare ALL DataBlood, 2016
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2016
- Blinatumomab treatment of older adults with relapsed/refractory B‐precursor acute lymphoblastic leukemia: Results from 2 phase 2 studiesCancer, 2016
- Moderate Intensive Chemotherapy Including CNS-Prophylaxis with Liposomal Cytarabine Is Feasible and effective in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Trial From the German Multicenter Study Group for Adult ALL (GMALL)Blood, 2012
- Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemiaCancer, 2008
- Myths and Lessons from the Adult/Pediatric Interface in Acute Lymphoblastic LeukemiaHematology-American Society Hematology Education Program, 2006